Journal article · 2018 · Open access

109 Comparative Efficacy and Tolerability of Lurasidone Versus Other Oral Atypical Antipsychotics for Pediatric Schizophrenia: A Network Meta Analysis

Celso Arango, Daisy Ng‐Mak, Elaine Finn, Aidan Byrne, Krithika Rajagopalan, Antony D Loebel

CNS Spectrums, 23(1), 70–71 · Published 1 February 2018 · DOI 10.1017/s1092852918000093

Open PDFView at the publisherCite this paper

In brief

“109 Comparative Efficacy and Tolerability of Lurasidone Versus Other Oral Atypical Antipsychotics for Pediatric Schizophrenia: A Network Meta Analysis” is a 2018 journal article by Celso Arango and 5 co-authors, published in CNS Spectrums. OpenAlex counts 2 citations as of 20 November 2026. It is open access: the full text is free to read at CNS Spectrums.

Citations
2
Most cited in
2021 (1)
Field-weighted impact
0.16
Authors
6

Abstract

Study Objective This analysis assessed the relative efficacy and tolerability of lurasidone versus other atypical antipsychotics in the treatment of pediatricschizophrenia. Methods A systematic literature review identified 13 randomized-controlled trials for the treatment of pediatric schizophrenia. A Bayesian network meta-analysis compared the efficacy and tolerability of the following atypical antipsychotics: aripiprazole, asenapine, clozapine, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, andziprasidone. Patients were 7-17 years old and trial duration ranged from 6-12 weeks. Outcomes included Positive and Negative Syndrome Scale (PANSS), Clinical Global Impressions-Severity (CGI-S), weight gain, all-cause treatment discontinuation, and extrapyramidal symptoms. Results from the fixed effect models were reported as mean differences for continuous outcomes and odds ratios for binary outcomes; each with a 95% credible interval. Results Lurasidone had significantly greater improvement compared with placebo for PANSS (-7.95 [-11.76, -4.16]) and CGI-S (-0.44 [-0.67, -0.22]), but did not differ from comparators. The differences in weight gain for lurasidone relative to comparators were as follows: clozapine (-3.81kg [-8.03, 0.42]), olanzapine (-3.62kg [-4.84, -2.41]), quetiapine (-2.13kg [-3.20, -1.08]), risperidone (-1.16kg [-2.14, -0.17]), asenapine (-0.98kg [-1.71, -0.24]), paliperidone (-0.85kg [-1.57, -0.14]), aripiprazole (-0.15kg [-0.88, 0.58]), and ziprasidone (0.38kg [-0.49, 1.24]); all were statistically significant except for clozapine, aripiprazole, and ziprasidone. Rates of all-cause discontinuation andextrapyramidal symptoms were similar for lurasidone and comparators, except aripiprazole and paliperidone, which had higher rates of all-cause discontinuation. Conclusions In this network meta-analysis of atypical antipsychotics for the treatment of adolescent schizophrenia, lurasidone was associated with similar efficacy, but less weight gain than active comparators. Funding Acknowledgements This study was funded by Sunovion Pharmaceuticals Inc.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Arango, C., Ng‐Mak, D., Finn, E., Byrne, A., Rajagopalan, K., & Loebel, A. D. (2018). 109 Comparative Efficacy and Tolerability of Lurasidone Versus Other Oral Atypical Antipsychotics for Pediatric Schizophrenia: A Network Meta Analysis. CNS Spectrums, 23(1), 70–71. https://doi.org/10.1017/s1092852918000093

MLA 9

Arango, Celso, et al. “109 Comparative Efficacy and Tolerability of Lurasidone Versus Other Oral Atypical Antipsychotics for Pediatric Schizophrenia: A Network Meta Analysis.” CNS Spectrums, vol. 23, no. 1, 2018, pp. 70–71. https://doi.org/10.1017/s1092852918000093.

Chicago

Arango, Celso, Daisy Ng‐Mak, Elaine Finn, Aidan Byrne, Krithika Rajagopalan, and Antony D Loebel. 2018. “109 Comparative Efficacy and Tolerability of Lurasidone Versus Other Oral Atypical Antipsychotics for Pediatric Schizophrenia: A Network Meta Analysis.” CNS Spectrums 23 (1): 70–71. https://doi.org/10.1017/s1092852918000093.

Harvard

Arango, C. et al. (2018) ‘109 Comparative Efficacy and Tolerability of Lurasidone Versus Other Oral Atypical Antipsychotics for Pediatric Schizophrenia: A Network Meta Analysis’, CNS Spectrums, 23(1), pp. 70–71. doi:10.1017/s1092852918000093.

IEEE

C. Arango, D. Ng‐Mak, E. Finn, A. Byrne, K. Rajagopalan, and A. D. Loebel, “109 Comparative Efficacy and Tolerability of Lurasidone Versus Other Oral Atypical Antipsychotics for Pediatric Schizophrenia: A Network Meta Analysis,” CNS Spectrums, vol. 23, no. 1, pp. 70–71, 2018, doi: 10.1017/s1092852918000093.

BibTeX

@article{arango2018comparative,
  title     = {{109 Comparative Efficacy and Tolerability of Lurasidone Versus Other Oral Atypical Antipsychotics for Pediatric Schizophrenia: A Network Meta Analysis}},
  author    = {Arango, Celso and Ng‐Mak, Daisy and Finn, Elaine and Byrne, Aidan and Rajagopalan, Krithika and Loebel, Antony D},
  journal   = {CNS Spectrums},
  year      = {2018},
  volume    = {23},
  number    = {1},
  pages     = {70--71},
  doi       = {10.1017/s1092852918000093},
  url       = {https://doi.org/10.1017/s1092852918000093}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment

  • lurasidone
  • pediatric schizophrenia
  • atypical antipsychotics
  • drug efficacy comparison
  • tolerability
  • weight gain
  • extrapyramidal symptoms
  • treatment discontinuation

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Arango, C., Ng‐Mak, D., Finn, E., Byrne, A., Rajagopalan, K., & Loebel, A. D. (2018). 109 Comparative Efficacy and Tolerability of Lurasidone Versus Other Oral Atypical Antipsychotics for Pediatric Schizophrenia: A Network Meta Analysis. CNS Spectrums, 23(1), 70–71. https://doi.org/10.1017/s1092852918000093

How many times has this paper been cited?

2 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at CNS Spectrums: sign in and open the PDF from this page.

Who wrote this paper?

Celso Arango, Daisy Ng‐Mak, Elaine Finn, Aidan Byrne, Krithika Rajagopalan, Antony D Loebel.

What is the DOI of this paper?

10.1017/s1092852918000093, permanently at https://doi.org/10.1017/s1092852918000093. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.